Ekso Bionics Prices $5.852 million Private Placement

Rhea-AI Summary

Ekso Bionics (Nasdaq: EKSO) priced a private placement announced Jan 21, 2026 to sell 5,852 shares of Series B preferred stock and warrants to buy up to 355,960 common shares. The preferred has a stated value of $1,000 per share and converts into 711,922 common shares at a conversion price of $8.22. Warrants are exercisable at $8.22, expire five years after initial exercise, and initial exercise begins six months after closing. Gross proceeds are expected to be about $5.9 million; net proceeds will be used for working capital and general corporate purposes.

Positive

• Gross proceeds of approximately $5.9 million
• Proceeds earmarked for working capital and general corporate purposes
• Exclusive placement agent engaged: Lake Street Capital Markets

Negative

• Preferred convertible into 711,922 common shares
• Warrants exercisable for 355,960 common shares
• Potential total dilution of 1,067,882 common shares if fully converted/exercised

Key Figures

Private placement size: $5.852 million Gross proceeds: $5.9 million Preferred shares issued: 5,852 shares +5 more

8 metrics

Private placement size $5.852 million Aggregate stated value of Series B Preferred Stock

Gross proceeds $5.9 million Expected gross proceeds before fees and expenses

Preferred shares issued 5,852 shares Series B Preferred Stock in the private placement

Stated value per share $1,000 per share Stated value of each Series B Preferred Stock share

Conversion shares 711,922 shares Common stock issuable upon conversion of Preferred Stock

Conversion price $8.22 per share Conversion price of Series B Preferred into common stock

Warrant coverage 355,960 shares Common shares underlying Warrants in the placement

Warrant exercise price $8.22 per share Exercise price of Warrants issued in the transaction

Market Reality Check

Price: $7.85 Vol: Volume 155,402 is well be...

low vol

$7.85 Last Close

Volume Volume 155,402 is well below the 6,178,969 share 20-day average, suggesting limited pre-news positioning. low

Technical Shares at $8.22 are trading above the $4.88 200-day MA, but remain 35.28% below the 52-week high.

Peers on Argus

EKSO was down 7.22% with mixed peer action: one peer (FEMY) up 0.55%, while othe...

1 Down

EKSO was down 7.22% with mixed peer action: one peer (FEMY) up 0.55%, while others like MHUA fell 27.18% and LUCY 7.97%, indicating a stock-specific reaction to capital-raising news rather than a uniform sector move.

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Distribution agreement	Positive	-5.7%	Exclusive U.S. distribution deal for BalanceTutor rehab system.
Oct 29	Equity offering	Neutral	+9.2%	Registered direct offering of common stock for general purposes.
Oct 28	Earnings update	Positive	-2.2%	Q3 2025 results with higher revenue, margins, and narrower net loss.
Jul 28	Earnings update	Negative	-27.4%	Q2 2025 results showing revenue decline and larger net loss.
Jul 21	Earnings call notice	Neutral	-2.5%	Announcement of Q2 2025 earnings release and conference call.

Pattern Detected

EKSO often experienced negative reactions to generally positive operational updates, while reactions to financing and neutral events have been mixed, suggesting news-driven volatility without a consistent directional pattern.

Recent Company History

Over the last six months, EKSO reported challenging Q2 2025 results with sharply lower revenue and a large -27.37% price drop, followed by improved Q3 2025 metrics but a modest decline. A $3.7M registered direct offering on Oct 29, 2025 saw a 9.15% gain, while a December 2025 U.S. distribution agreement for BalanceTutor coincided with a -5.66% move. Against this backdrop, the new private placement continues a pattern of capital raises alongside ongoing strategic and operational initiatives.

Market Pulse Summary

This announcement details a private placement of Series B Preferred Stock and warrants that could tr...

Analysis

This announcement details a private placement of Series B Preferred Stock and warrants that could translate into 711,922 conversion shares and 355,960 warrant shares at $8.22. Expected gross proceeds of about $5.9M are earmarked for working capital and general corporate purposes, continuing a pattern of equity financing. Investors may track how this capital supports execution relative to prior earnings trends and whether additional issuances or balance sheet actions follow from recent strategic initiatives.

Key Terms

private placement, series b preferred stock, warrants, conversion price, +3 more

7 terms

private placement financial

"shares of common stock of the Company in a private placement transaction"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

series b preferred stock financial

"an aggregate of 5,852 shares of the Company’s Series B Preferred Stock"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

warrants financial

"and warrants (the “Warrants”) to purchase up to an aggregate of 355,960 shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

conversion price financial

"convertible ... into an aggregate of 711,922 shares ... at a conversion price of $8.22 per share"

The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.

exercise price financial

"The Warrants will be exercisable at an exercise price of $8.22 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

securities purchase agreements financial

"it entered into securities purchase agreements with certain institutional and accredited investors"

A securities purchase agreement is a legal contract that spells out the terms when a company sells stocks, bonds, or other investment instruments to buyers. It lays out price, how many securities change hands, any promises or protections for each side, and when the sale is completed—like a detailed sales contract for investments. Investors care because it determines ownership stakes, potential dilution, rights attached to the securities, and conditions that affect the company’s future value.

registration statement regulatory

"may not be reoffered or resold ... except pursuant to an effective registration statement"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. Not financial advice.

SAN RAFAEL, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that on January 20, 2026 it entered into securities purchase agreements with certain institutional and accredited investors for the purchase and sale of an aggregate of 5,852 shares of the Company’s Series B Preferred Stock (the “Preferred Stock”) and warrants (the “Warrants”) to purchase up to an aggregate of 355,960 shares of common stock of the Company in a private placement transaction (the “Private Placement”).

The shares of Preferred Stock will have a stated value of $1,000 per share and be convertible at any time and from time to time into an aggregate of 711,922 shares of common stock of the Company at a conversion price of $8.22 per share. The holders of the Preferred Stock will be entitled to vote together with the holders of the Company’s common stock on an as-converted basis, subject to certain limitations. The Warrants will be exercisable at an exercise price of $8.22 per share and will expire five years from their initial exercise date, which shall be six months after the closing of the Private Placement. The exercise of the Warrants will be subject to certain limitations, including that the holder does not at the time of such exercise hold any shares of the Preferred Stock or the common stock into which such Preferred Stock had converted.

The closing of the Private Placement is expected to occur on or about January 22, 2026, subject to the satisfaction of customary closing conditions.

The gross proceeds to the Company from the Private Placement are expected to be approximately $5.9 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Private Placement for working capital and general corporate purposes.

Lake Street Capital Markets, LLC is acting as the exclusive placement agent for the Private Placement.

The securities described above were offered in a private placement exempt from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), as a transaction not involving a public offering and have not been registered under the Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities or any other securities of the Company, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Ekso Bionics

Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.”

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the timing and details of the Company’s offering of securities and the use of proceeds from such offering. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s liquidity position and its ability to raise additional funds, as well as changes in general economic and market conditions. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company’s most recently filed Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q. Any forward-looking statements made in this press release speak only as of the date of this press release. The Company does not undertake to update these forward-looking statements, except as required by law.

Contact:

Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@eksobionics.com

FAQ

What did Ekso Bionics announce on January 21, 2026 regarding a private placement (EKSO)?

Ekso priced a private placement to sell 5,852 Series B preferred shares and warrants for gross proceeds of about $5.9 million.

How many common shares can Ekso preferred stock convert into and at what price (EKSO)?

The Series B preferred stock converts into 711,922 common shares at a conversion price of $8.22 per share.

How many shares do the Ekso warrants cover and what is the exercise price (EKSO)?

Warrants cover up to 355,960 common shares and are exercisable at $8.22 per share, expiring five years after initial exercise.

When is the Ekso private placement expected to close and when can warrants be first exercised (EKSO)?

The closing is expected on or about January 22, 2026, and initial warrant exercise begins six months after closing.

What will Ekso use the proceeds from the private placement for (EKSO)?

The company intends to use net proceeds for working capital and general corporate purposes.

Are there resale restrictions on the securities sold in Ekso's private placement (EKSO)?

Yes; the securities were sold in a private placement exempt from registration and may not be resold in the U.S. except via registration or an applicable exemption.